Global Hadron Therapy

Hadron Therapy Comprehensive Study by Type (Electron Beam, Neutron Beam, Alpha Particle Beam, Proton Beam, Carbon Ion Beam, Beta Particle Beam), Application (Treatment Applications, Research Applications), Cancer Type (Pediatric Cancer, Bone and Soft Tissue Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Eye Cancer, Head & Neck Cancer, Others), End User (Hospitals, Cancer Research Centers, Clinics) Players and Region - Global Market Outlook to 2026

Hadron Therapy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Technological advancements including reduced contrary effects and less radiation dose transmitted to healthy tissues during the radiation procedure will help to boost global Hadron therapy market in the forecasted period. Hardon therapy is also known as ion beam therapy or particle beam therapy. Hardon therapy is a type of therapy used ionizing radiation for cancer treatment. This therapy destroys the cancerous cells by damaging their DNA. The exclusive property of hadron therapy is physical and radiobiological properties of particles, which permit them to penetrate the tissues with less diffusion and transfer supreme energy within a specific area.
This growth is primarily driven by Increase in Prevalence’s Of Cancer and Upsurge in Healthcare Disbursement.

Globally, a noticeable market trend is evident Growing Access to Medical Insurance . The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Koninklijke Philips N.V. (Netherlands), Ion Beam Applications SA (Belgium), Advanced Oncotherapy (United Kingdom), Hitachi, Ltd. (Japan), Varian Medical Systems, Inc. (United States), Optivus Proton Therapy, Inc. (United States), Mevion Medical Systems (United States), ProTom International (United States), Mitsubishi Electric Corporation (Japan) and Sumitomo Corporation (Japan) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 25th April 2019, Royal Philips a global leader in health technology has launched IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, increase efficiency and allow operational superiority in radiotherapy departments.
On 7th March 2019, Royal Philips), a global leader in health technology has acquired the Healthcare Information Systems business of Carestream Health Inc., a United States-based provider of medical imaging and healthcare IT solutions for hospitals, imaging centers, and specialty medical clinics.

Market Drivers
  • Increase in Prevalence’s Of Cancer
  • Upsurge in Healthcare Disbursement

Market Trend
  • Growing Access to Medical Insurance
  • Technological Advancements in Cancer Treatment Therapies

Restraints
  • Dearth of Awareness about Hadron Therapy
  • Less Number of Treatment Providers

Opportunities
Huge Opportunity in Emerging Countries and Growing Healthcare Expenditure in Developing Nations
Challenges
High Product Developmental Cost

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Hadron Therapy Study Sheds Light on
— The Hadron Therapy Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Hadron Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Hadron Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Electron Beam
  • Neutron Beam
  • Alpha Particle Beam
  • Proton Beam
  • Carbon Ion Beam
  • Beta Particle Beam
By Application
  • Treatment Applications
  • Research Applications
By Cancer Type
  • Pediatric Cancer
  • Bone and Soft Tissue Cancer
  • Prostate Cancer
  • Lung Cancer
  • Liver Cancer
  • Eye Cancer
  • Head & Neck Cancer
  • Others

By End User
  • Hospitals
  • Cancer Research Centers
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Prevalence’s Of Cancer
      • 3.2.2. Upsurge in Healthcare Disbursement
    • 3.3. Market Challenges
      • 3.3.1. High Product Developmental Cost
    • 3.4. Market Trends
      • 3.4.1. Growing Access to Medical Insurance
      • 3.4.2. Technological Advancements in Cancer Treatment Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hadron Therapy, by Type, Application, Cancer Type, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hadron Therapy (Value)
      • 5.2.1. Global Hadron Therapy by: Type (Value)
        • 5.2.1.1. Electron Beam
        • 5.2.1.2. Neutron Beam
        • 5.2.1.3. Alpha Particle Beam
        • 5.2.1.4. Proton Beam
        • 5.2.1.5. Carbon Ion Beam
        • 5.2.1.6. Beta Particle Beam
      • 5.2.2. Global Hadron Therapy by: Application (Value)
        • 5.2.2.1. Treatment Applications
        • 5.2.2.2. Research Applications
      • 5.2.3. Global Hadron Therapy by: Cancer Type (Value)
        • 5.2.3.1. Pediatric Cancer
        • 5.2.3.2. Bone and Soft Tissue Cancer
        • 5.2.3.3. Prostate Cancer
        • 5.2.3.4. Lung Cancer
        • 5.2.3.5. Liver Cancer
        • 5.2.3.6. Eye Cancer
        • 5.2.3.7. Head & Neck Cancer
        • 5.2.3.8. Others
      • 5.2.4. Global Hadron Therapy by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Cancer Research Centers
        • 5.2.4.3. Clinics
      • 5.2.5. Global Hadron Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hadron Therapy (Price)
      • 5.3.1. Global Hadron Therapy by: Type (Price)
  • 6. Hadron Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Koninklijke Philips N.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ion Beam Applications SA (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Advanced Oncotherapy (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hitachi, Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Varian Medical Systems, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Optivus Proton Therapy, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mevion Medical Systems (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ProTom International (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mitsubishi Electric Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sumitomo Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hadron Therapy Sale, by Type, Application, Cancer Type, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hadron Therapy (Value)
      • 7.2.1. Global Hadron Therapy by: Type (Value)
        • 7.2.1.1. Electron Beam
        • 7.2.1.2. Neutron Beam
        • 7.2.1.3. Alpha Particle Beam
        • 7.2.1.4. Proton Beam
        • 7.2.1.5. Carbon Ion Beam
        • 7.2.1.6. Beta Particle Beam
      • 7.2.2. Global Hadron Therapy by: Application (Value)
        • 7.2.2.1. Treatment Applications
        • 7.2.2.2. Research Applications
      • 7.2.3. Global Hadron Therapy by: Cancer Type (Value)
        • 7.2.3.1. Pediatric Cancer
        • 7.2.3.2. Bone and Soft Tissue Cancer
        • 7.2.3.3. Prostate Cancer
        • 7.2.3.4. Lung Cancer
        • 7.2.3.5. Liver Cancer
        • 7.2.3.6. Eye Cancer
        • 7.2.3.7. Head & Neck Cancer
        • 7.2.3.8. Others
      • 7.2.4. Global Hadron Therapy by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Cancer Research Centers
        • 7.2.4.3. Clinics
      • 7.2.5. Global Hadron Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hadron Therapy (Price)
      • 7.3.1. Global Hadron Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hadron Therapy: by Type(USD Million)
  • Table 2. Hadron Therapy Electron Beam , by Region USD Million (2015-2020)
  • Table 3. Hadron Therapy Neutron Beam , by Region USD Million (2015-2020)
  • Table 4. Hadron Therapy Alpha Particle Beam , by Region USD Million (2015-2020)
  • Table 5. Hadron Therapy Proton Beam , by Region USD Million (2015-2020)
  • Table 6. Hadron Therapy Carbon Ion Beam , by Region USD Million (2015-2020)
  • Table 7. Hadron Therapy Beta Particle Beam , by Region USD Million (2015-2020)
  • Table 8. Hadron Therapy: by Application(USD Million)
  • Table 9. Hadron Therapy Treatment Applications , by Region USD Million (2015-2020)
  • Table 10. Hadron Therapy Research Applications , by Region USD Million (2015-2020)
  • Table 11. Hadron Therapy: by Cancer Type(USD Million)
  • Table 12. Hadron Therapy Pediatric Cancer , by Region USD Million (2015-2020)
  • Table 13. Hadron Therapy Bone and Soft Tissue Cancer , by Region USD Million (2015-2020)
  • Table 14. Hadron Therapy Prostate Cancer , by Region USD Million (2015-2020)
  • Table 15. Hadron Therapy Lung Cancer , by Region USD Million (2015-2020)
  • Table 16. Hadron Therapy Liver Cancer , by Region USD Million (2015-2020)
  • Table 17. Hadron Therapy Eye Cancer , by Region USD Million (2015-2020)
  • Table 18. Hadron Therapy Head & Neck Cancer , by Region USD Million (2015-2020)
  • Table 19. Hadron Therapy Others , by Region USD Million (2015-2020)
  • Table 20. Hadron Therapy: by End User(USD Million)
  • Table 21. Hadron Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 22. Hadron Therapy Cancer Research Centers , by Region USD Million (2015-2020)
  • Table 23. Hadron Therapy Clinics , by Region USD Million (2015-2020)
  • Table 24. South America Hadron Therapy, by Country USD Million (2015-2020)
  • Table 25. South America Hadron Therapy, by Type USD Million (2015-2020)
  • Table 26. South America Hadron Therapy, by Application USD Million (2015-2020)
  • Table 27. South America Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 28. South America Hadron Therapy, by End User USD Million (2015-2020)
  • Table 29. Brazil Hadron Therapy, by Type USD Million (2015-2020)
  • Table 30. Brazil Hadron Therapy, by Application USD Million (2015-2020)
  • Table 31. Brazil Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 32. Brazil Hadron Therapy, by End User USD Million (2015-2020)
  • Table 33. Argentina Hadron Therapy, by Type USD Million (2015-2020)
  • Table 34. Argentina Hadron Therapy, by Application USD Million (2015-2020)
  • Table 35. Argentina Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 36. Argentina Hadron Therapy, by End User USD Million (2015-2020)
  • Table 37. Rest of South America Hadron Therapy, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Hadron Therapy, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 40. Rest of South America Hadron Therapy, by End User USD Million (2015-2020)
  • Table 41. Asia Pacific Hadron Therapy, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Hadron Therapy, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Hadron Therapy, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 45. Asia Pacific Hadron Therapy, by End User USD Million (2015-2020)
  • Table 46. China Hadron Therapy, by Type USD Million (2015-2020)
  • Table 47. China Hadron Therapy, by Application USD Million (2015-2020)
  • Table 48. China Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 49. China Hadron Therapy, by End User USD Million (2015-2020)
  • Table 50. Japan Hadron Therapy, by Type USD Million (2015-2020)
  • Table 51. Japan Hadron Therapy, by Application USD Million (2015-2020)
  • Table 52. Japan Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 53. Japan Hadron Therapy, by End User USD Million (2015-2020)
  • Table 54. India Hadron Therapy, by Type USD Million (2015-2020)
  • Table 55. India Hadron Therapy, by Application USD Million (2015-2020)
  • Table 56. India Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 57. India Hadron Therapy, by End User USD Million (2015-2020)
  • Table 58. South Korea Hadron Therapy, by Type USD Million (2015-2020)
  • Table 59. South Korea Hadron Therapy, by Application USD Million (2015-2020)
  • Table 60. South Korea Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 61. South Korea Hadron Therapy, by End User USD Million (2015-2020)
  • Table 62. Taiwan Hadron Therapy, by Type USD Million (2015-2020)
  • Table 63. Taiwan Hadron Therapy, by Application USD Million (2015-2020)
  • Table 64. Taiwan Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 65. Taiwan Hadron Therapy, by End User USD Million (2015-2020)
  • Table 66. Australia Hadron Therapy, by Type USD Million (2015-2020)
  • Table 67. Australia Hadron Therapy, by Application USD Million (2015-2020)
  • Table 68. Australia Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 69. Australia Hadron Therapy, by End User USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Hadron Therapy, by Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Hadron Therapy, by Application USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Hadron Therapy, by End User USD Million (2015-2020)
  • Table 74. Europe Hadron Therapy, by Country USD Million (2015-2020)
  • Table 75. Europe Hadron Therapy, by Type USD Million (2015-2020)
  • Table 76. Europe Hadron Therapy, by Application USD Million (2015-2020)
  • Table 77. Europe Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 78. Europe Hadron Therapy, by End User USD Million (2015-2020)
  • Table 79. Germany Hadron Therapy, by Type USD Million (2015-2020)
  • Table 80. Germany Hadron Therapy, by Application USD Million (2015-2020)
  • Table 81. Germany Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 82. Germany Hadron Therapy, by End User USD Million (2015-2020)
  • Table 83. France Hadron Therapy, by Type USD Million (2015-2020)
  • Table 84. France Hadron Therapy, by Application USD Million (2015-2020)
  • Table 85. France Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 86. France Hadron Therapy, by End User USD Million (2015-2020)
  • Table 87. Italy Hadron Therapy, by Type USD Million (2015-2020)
  • Table 88. Italy Hadron Therapy, by Application USD Million (2015-2020)
  • Table 89. Italy Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 90. Italy Hadron Therapy, by End User USD Million (2015-2020)
  • Table 91. United Kingdom Hadron Therapy, by Type USD Million (2015-2020)
  • Table 92. United Kingdom Hadron Therapy, by Application USD Million (2015-2020)
  • Table 93. United Kingdom Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 94. United Kingdom Hadron Therapy, by End User USD Million (2015-2020)
  • Table 95. Netherlands Hadron Therapy, by Type USD Million (2015-2020)
  • Table 96. Netherlands Hadron Therapy, by Application USD Million (2015-2020)
  • Table 97. Netherlands Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 98. Netherlands Hadron Therapy, by End User USD Million (2015-2020)
  • Table 99. Rest of Europe Hadron Therapy, by Type USD Million (2015-2020)
  • Table 100. Rest of Europe Hadron Therapy, by Application USD Million (2015-2020)
  • Table 101. Rest of Europe Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 102. Rest of Europe Hadron Therapy, by End User USD Million (2015-2020)
  • Table 103. MEA Hadron Therapy, by Country USD Million (2015-2020)
  • Table 104. MEA Hadron Therapy, by Type USD Million (2015-2020)
  • Table 105. MEA Hadron Therapy, by Application USD Million (2015-2020)
  • Table 106. MEA Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 107. MEA Hadron Therapy, by End User USD Million (2015-2020)
  • Table 108. Middle East Hadron Therapy, by Type USD Million (2015-2020)
  • Table 109. Middle East Hadron Therapy, by Application USD Million (2015-2020)
  • Table 110. Middle East Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 111. Middle East Hadron Therapy, by End User USD Million (2015-2020)
  • Table 112. Africa Hadron Therapy, by Type USD Million (2015-2020)
  • Table 113. Africa Hadron Therapy, by Application USD Million (2015-2020)
  • Table 114. Africa Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 115. Africa Hadron Therapy, by End User USD Million (2015-2020)
  • Table 116. North America Hadron Therapy, by Country USD Million (2015-2020)
  • Table 117. North America Hadron Therapy, by Type USD Million (2015-2020)
  • Table 118. North America Hadron Therapy, by Application USD Million (2015-2020)
  • Table 119. North America Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 120. North America Hadron Therapy, by End User USD Million (2015-2020)
  • Table 121. United States Hadron Therapy, by Type USD Million (2015-2020)
  • Table 122. United States Hadron Therapy, by Application USD Million (2015-2020)
  • Table 123. United States Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 124. United States Hadron Therapy, by End User USD Million (2015-2020)
  • Table 125. Canada Hadron Therapy, by Type USD Million (2015-2020)
  • Table 126. Canada Hadron Therapy, by Application USD Million (2015-2020)
  • Table 127. Canada Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 128. Canada Hadron Therapy, by End User USD Million (2015-2020)
  • Table 129. Mexico Hadron Therapy, by Type USD Million (2015-2020)
  • Table 130. Mexico Hadron Therapy, by Application USD Million (2015-2020)
  • Table 131. Mexico Hadron Therapy, by Cancer Type USD Million (2015-2020)
  • Table 132. Mexico Hadron Therapy, by End User USD Million (2015-2020)
  • Table 133. Hadron Therapy: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Hadron Therapy: by Type(USD Million)
  • Table 145. Hadron Therapy Electron Beam , by Region USD Million (2021-2026)
  • Table 146. Hadron Therapy Neutron Beam , by Region USD Million (2021-2026)
  • Table 147. Hadron Therapy Alpha Particle Beam , by Region USD Million (2021-2026)
  • Table 148. Hadron Therapy Proton Beam , by Region USD Million (2021-2026)
  • Table 149. Hadron Therapy Carbon Ion Beam , by Region USD Million (2021-2026)
  • Table 150. Hadron Therapy Beta Particle Beam , by Region USD Million (2021-2026)
  • Table 151. Hadron Therapy: by Application(USD Million)
  • Table 152. Hadron Therapy Treatment Applications , by Region USD Million (2021-2026)
  • Table 153. Hadron Therapy Research Applications , by Region USD Million (2021-2026)
  • Table 154. Hadron Therapy: by Cancer Type(USD Million)
  • Table 155. Hadron Therapy Pediatric Cancer , by Region USD Million (2021-2026)
  • Table 156. Hadron Therapy Bone and Soft Tissue Cancer , by Region USD Million (2021-2026)
  • Table 157. Hadron Therapy Prostate Cancer , by Region USD Million (2021-2026)
  • Table 158. Hadron Therapy Lung Cancer , by Region USD Million (2021-2026)
  • Table 159. Hadron Therapy Liver Cancer , by Region USD Million (2021-2026)
  • Table 160. Hadron Therapy Eye Cancer , by Region USD Million (2021-2026)
  • Table 161. Hadron Therapy Head & Neck Cancer , by Region USD Million (2021-2026)
  • Table 162. Hadron Therapy Others , by Region USD Million (2021-2026)
  • Table 163. Hadron Therapy: by End User(USD Million)
  • Table 164. Hadron Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 165. Hadron Therapy Cancer Research Centers , by Region USD Million (2021-2026)
  • Table 166. Hadron Therapy Clinics , by Region USD Million (2021-2026)
  • Table 167. South America Hadron Therapy, by Country USD Million (2021-2026)
  • Table 168. South America Hadron Therapy, by Type USD Million (2021-2026)
  • Table 169. South America Hadron Therapy, by Application USD Million (2021-2026)
  • Table 170. South America Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 171. South America Hadron Therapy, by End User USD Million (2021-2026)
  • Table 172. Brazil Hadron Therapy, by Type USD Million (2021-2026)
  • Table 173. Brazil Hadron Therapy, by Application USD Million (2021-2026)
  • Table 174. Brazil Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 175. Brazil Hadron Therapy, by End User USD Million (2021-2026)
  • Table 176. Argentina Hadron Therapy, by Type USD Million (2021-2026)
  • Table 177. Argentina Hadron Therapy, by Application USD Million (2021-2026)
  • Table 178. Argentina Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 179. Argentina Hadron Therapy, by End User USD Million (2021-2026)
  • Table 180. Rest of South America Hadron Therapy, by Type USD Million (2021-2026)
  • Table 181. Rest of South America Hadron Therapy, by Application USD Million (2021-2026)
  • Table 182. Rest of South America Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 183. Rest of South America Hadron Therapy, by End User USD Million (2021-2026)
  • Table 184. Asia Pacific Hadron Therapy, by Country USD Million (2021-2026)
  • Table 185. Asia Pacific Hadron Therapy, by Type USD Million (2021-2026)
  • Table 186. Asia Pacific Hadron Therapy, by Application USD Million (2021-2026)
  • Table 187. Asia Pacific Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 188. Asia Pacific Hadron Therapy, by End User USD Million (2021-2026)
  • Table 189. China Hadron Therapy, by Type USD Million (2021-2026)
  • Table 190. China Hadron Therapy, by Application USD Million (2021-2026)
  • Table 191. China Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 192. China Hadron Therapy, by End User USD Million (2021-2026)
  • Table 193. Japan Hadron Therapy, by Type USD Million (2021-2026)
  • Table 194. Japan Hadron Therapy, by Application USD Million (2021-2026)
  • Table 195. Japan Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 196. Japan Hadron Therapy, by End User USD Million (2021-2026)
  • Table 197. India Hadron Therapy, by Type USD Million (2021-2026)
  • Table 198. India Hadron Therapy, by Application USD Million (2021-2026)
  • Table 199. India Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 200. India Hadron Therapy, by End User USD Million (2021-2026)
  • Table 201. South Korea Hadron Therapy, by Type USD Million (2021-2026)
  • Table 202. South Korea Hadron Therapy, by Application USD Million (2021-2026)
  • Table 203. South Korea Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 204. South Korea Hadron Therapy, by End User USD Million (2021-2026)
  • Table 205. Taiwan Hadron Therapy, by Type USD Million (2021-2026)
  • Table 206. Taiwan Hadron Therapy, by Application USD Million (2021-2026)
  • Table 207. Taiwan Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 208. Taiwan Hadron Therapy, by End User USD Million (2021-2026)
  • Table 209. Australia Hadron Therapy, by Type USD Million (2021-2026)
  • Table 210. Australia Hadron Therapy, by Application USD Million (2021-2026)
  • Table 211. Australia Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 212. Australia Hadron Therapy, by End User USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Hadron Therapy, by Type USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Hadron Therapy, by Application USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Hadron Therapy, by End User USD Million (2021-2026)
  • Table 217. Europe Hadron Therapy, by Country USD Million (2021-2026)
  • Table 218. Europe Hadron Therapy, by Type USD Million (2021-2026)
  • Table 219. Europe Hadron Therapy, by Application USD Million (2021-2026)
  • Table 220. Europe Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 221. Europe Hadron Therapy, by End User USD Million (2021-2026)
  • Table 222. Germany Hadron Therapy, by Type USD Million (2021-2026)
  • Table 223. Germany Hadron Therapy, by Application USD Million (2021-2026)
  • Table 224. Germany Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 225. Germany Hadron Therapy, by End User USD Million (2021-2026)
  • Table 226. France Hadron Therapy, by Type USD Million (2021-2026)
  • Table 227. France Hadron Therapy, by Application USD Million (2021-2026)
  • Table 228. France Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 229. France Hadron Therapy, by End User USD Million (2021-2026)
  • Table 230. Italy Hadron Therapy, by Type USD Million (2021-2026)
  • Table 231. Italy Hadron Therapy, by Application USD Million (2021-2026)
  • Table 232. Italy Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 233. Italy Hadron Therapy, by End User USD Million (2021-2026)
  • Table 234. United Kingdom Hadron Therapy, by Type USD Million (2021-2026)
  • Table 235. United Kingdom Hadron Therapy, by Application USD Million (2021-2026)
  • Table 236. United Kingdom Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 237. United Kingdom Hadron Therapy, by End User USD Million (2021-2026)
  • Table 238. Netherlands Hadron Therapy, by Type USD Million (2021-2026)
  • Table 239. Netherlands Hadron Therapy, by Application USD Million (2021-2026)
  • Table 240. Netherlands Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 241. Netherlands Hadron Therapy, by End User USD Million (2021-2026)
  • Table 242. Rest of Europe Hadron Therapy, by Type USD Million (2021-2026)
  • Table 243. Rest of Europe Hadron Therapy, by Application USD Million (2021-2026)
  • Table 244. Rest of Europe Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 245. Rest of Europe Hadron Therapy, by End User USD Million (2021-2026)
  • Table 246. MEA Hadron Therapy, by Country USD Million (2021-2026)
  • Table 247. MEA Hadron Therapy, by Type USD Million (2021-2026)
  • Table 248. MEA Hadron Therapy, by Application USD Million (2021-2026)
  • Table 249. MEA Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 250. MEA Hadron Therapy, by End User USD Million (2021-2026)
  • Table 251. Middle East Hadron Therapy, by Type USD Million (2021-2026)
  • Table 252. Middle East Hadron Therapy, by Application USD Million (2021-2026)
  • Table 253. Middle East Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 254. Middle East Hadron Therapy, by End User USD Million (2021-2026)
  • Table 255. Africa Hadron Therapy, by Type USD Million (2021-2026)
  • Table 256. Africa Hadron Therapy, by Application USD Million (2021-2026)
  • Table 257. Africa Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 258. Africa Hadron Therapy, by End User USD Million (2021-2026)
  • Table 259. North America Hadron Therapy, by Country USD Million (2021-2026)
  • Table 260. North America Hadron Therapy, by Type USD Million (2021-2026)
  • Table 261. North America Hadron Therapy, by Application USD Million (2021-2026)
  • Table 262. North America Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 263. North America Hadron Therapy, by End User USD Million (2021-2026)
  • Table 264. United States Hadron Therapy, by Type USD Million (2021-2026)
  • Table 265. United States Hadron Therapy, by Application USD Million (2021-2026)
  • Table 266. United States Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 267. United States Hadron Therapy, by End User USD Million (2021-2026)
  • Table 268. Canada Hadron Therapy, by Type USD Million (2021-2026)
  • Table 269. Canada Hadron Therapy, by Application USD Million (2021-2026)
  • Table 270. Canada Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 271. Canada Hadron Therapy, by End User USD Million (2021-2026)
  • Table 272. Mexico Hadron Therapy, by Type USD Million (2021-2026)
  • Table 273. Mexico Hadron Therapy, by Application USD Million (2021-2026)
  • Table 274. Mexico Hadron Therapy, by Cancer Type USD Million (2021-2026)
  • Table 275. Mexico Hadron Therapy, by End User USD Million (2021-2026)
  • Table 276. Hadron Therapy: by Type(USD/Units)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hadron Therapy: by Type USD Million (2015-2020)
  • Figure 5. Global Hadron Therapy: by Application USD Million (2015-2020)
  • Figure 6. Global Hadron Therapy: by Cancer Type USD Million (2015-2020)
  • Figure 7. Global Hadron Therapy: by End User USD Million (2015-2020)
  • Figure 8. South America Hadron Therapy Share (%), by Country
  • Figure 9. Asia Pacific Hadron Therapy Share (%), by Country
  • Figure 10. Europe Hadron Therapy Share (%), by Country
  • Figure 11. MEA Hadron Therapy Share (%), by Country
  • Figure 12. North America Hadron Therapy Share (%), by Country
  • Figure 13. Global Hadron Therapy: by Type USD/Units (2015-2020)
  • Figure 14. Global Hadron Therapy share by Players 2020 (%)
  • Figure 15. Global Hadron Therapy share by Players (Top 3) 2020(%)
  • Figure 16. Global Hadron Therapy share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 20. Ion Beam Applications SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 21. Ion Beam Applications SA (Belgium) Revenue: by Geography 2020
  • Figure 22. Advanced Oncotherapy (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Advanced Oncotherapy (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Hitachi, Ltd. (Japan) Revenue: by Geography 2020
  • Figure 26. Varian Medical Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Varian Medical Systems, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Optivus Proton Therapy, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Optivus Proton Therapy, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Mevion Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 31. Mevion Medical Systems (United States) Revenue: by Geography 2020
  • Figure 32. ProTom International (United States) Revenue, Net Income and Gross profit
  • Figure 33. ProTom International (United States) Revenue: by Geography 2020
  • Figure 34. Mitsubishi Electric Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Mitsubishi Electric Corporation (Japan) Revenue: by Geography 2020
  • Figure 36. Sumitomo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Sumitomo Corporation (Japan) Revenue: by Geography 2020
  • Figure 38. Global Hadron Therapy: by Type USD Million (2021-2026)
  • Figure 39. Global Hadron Therapy: by Application USD Million (2021-2026)
  • Figure 40. Global Hadron Therapy: by Cancer Type USD Million (2021-2026)
  • Figure 41. Global Hadron Therapy: by End User USD Million (2021-2026)
  • Figure 42. South America Hadron Therapy Share (%), by Country
  • Figure 43. Asia Pacific Hadron Therapy Share (%), by Country
  • Figure 44. Europe Hadron Therapy Share (%), by Country
  • Figure 45. MEA Hadron Therapy Share (%), by Country
  • Figure 46. North America Hadron Therapy Share (%), by Country
  • Figure 47. Global Hadron Therapy: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Koninklijke Philips N.V. (Netherlands)
  • Ion Beam Applications SA (Belgium)
  • Advanced Oncotherapy (United Kingdom)
  • Hitachi, Ltd. (Japan)
  • Varian Medical Systems, Inc. (United States)
  • Optivus Proton Therapy, Inc. (United States)
  • Mevion Medical Systems (United States)
  • ProTom International (United States)
  • Mitsubishi Electric Corporation (Japan)
  • Sumitomo Corporation (Japan)
Additional players considered in the study are as follows:
ProNova Solutions, LLC (United States) , Provision Healthcare (United States) , Danfysik A/S (Denmark)
Select User Access Type

Key Highlights of Report


Feb 2022 246 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hadron Therapy Quantitative research analysis
Global Hadron Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Hadron Therapy market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Hadron Therapy market are Koninklijke Philips N.V. (Netherlands), Ion Beam Applications SA (Belgium), Advanced Oncotherapy (United Kingdom), Hitachi, Ltd. (Japan), Varian Medical Systems, Inc. (United States), Optivus Proton Therapy, Inc. (United States), Mevion Medical Systems (United States), ProTom International (United States), Mitsubishi Electric Corporation (Japan) and Sumitomo Corporation (Japan), to name a few.
North America is dominating the Hadron Therapy Market.

Know More About Global Hadron Therapy Report?

Have a Query? Click Here

Other Related Reports

Adenomyosis Treatment Comprehensive Study by Type (Focal, Adenomyoma, Diffuse, Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Treatment (Anti-inflammatory Drugs (ibup...
$ 3750
Aneurysmal Subarachnoid Hemorrhage Comprehensive Study by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, Transcranial Dop...
$ 3650
Phenylketonuria Treatment Comprehensive Study by Type (Drugs (Kuvan, Pegvaliase and Others), Dietary Supplement), Application (Hospital Pharmacies, Drug Stores, Online Pharmacies, Pediatric Clinics),...
$ 3650
Nerve Repair and Regeneration Comprehensive Study by Type (Neurostimulation Devices, Neuromodulation Devices (Sacral Nerve Stimulation Devices (SNS), Vagus Nerve Stimulation Devices (VNS), Spinal Cor...
$ 3750
mRNA Vaccines & Therapeutics Comprehensive Study by Type (Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, In...
$ 3750
Antibody Services Comprehensive Study by Type (Polyclonal antibody, Monoclonal antibody, Murine, Chimeric, Humanize, Other), Application (Gastroenterology, Rheumatology, Infection, Cardiology, Hemato...
$ 3650